[Featured Stock] D&D Pharmatech surges on MASH Phase 2 final data release... Technology transfer expectations highlighted

D&D Pharmatech's stock is strong after releasing the final 48-week results of its Phase 2 clinical trial for its MASH treatment candidate 'Zabopeglutide (DD01)'. The company secured statistical significance compared to placebo in key biopsy indicators, leading to increased expectations for global technology transfer and an influx of buying interest.

Get the next 8/10 catalyst

Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 48.6%.

Join Telegram channel or scan with phone →